INTRODUCTION
Familial hypercholesterolaemia (FH) is a condition caused by mutations in the low-density lipoprotein receptor (LDLR) gene and characterised by high-circulating levels of LDL cholesterol leading to early development of atherosclerosis. As a monogenic loss of function disorder, FH has been the subject of a number of previous studies into the possibility of using gene-replacement gene therapy to treat the condition, with the main focus being on viral delivery systems such as retrovirus, 1-5 adenovirus [6] [7] [8] [9] [10] [11] [12] and adeno-associated virus, 13, 14 and including an early clinical trial. 2 Overall, these studies showed some evidence of long-term therapeutic effect with varying degrees of success. In spite of this research effort, an effective gene therapy protocol for use in the clinic to treat FH remains elusive.
FH represents a significant challenge for gene therapy. This is because any gene therapy treatment has to overcome constitutive cholesterol production in the liver to result in clinically relevant lowering of blood cholesterol levels. This is further complicated by the evidence that hepatocytes may only be metabolically able to take up and process a limited amount of cholesterol before insoluble cellular accumulations occur resulting in cell death. 15, 16 Expression from the LDLR genomic locus is controlled by levels of intracellular cholesterol. When intracellular levels of cholesterol fall LDLR expression is triggered by the binding of sterol response element binding proteins to the sterol response elements in the promoter region. [17] [18] [19] This drives expression of the LDLR, which binds and internalises LDL particles from the circulation. As cellular cholesterol stores become replete, the sterol response element binding proteins become less active and expression from the LDLR locus is repressed.
We propose that, for a gene therapy protocol to be successful for FH, several improvements may enhance likelihood of therapeutic success. First, any gene therapy vector would benefit from regulatory elements to ensure physiologically controlled expression of the LDLR. Second, the delivery efficiency should be such that enough cells express the transgene to produce a clinically significant lowering of cholesterol; and third, the vector needs to have efficient expression over a long period of time.
With these three considerations in mind, we have previously developed mini-gene vectors, in which expression of a cDNA is controlled by 10 kb of genomic DNA from the native human LDLR locus incorporating the full promoter including the three sterol response elements in the 5 untranslated region. 20 We have shown that these vectors confer full complementation of LDLR function under physiological regulation in vitro in Ldlr À/À cells and that this correlates to functional complementation through the correct binding and internalisation of LDL molecules. Our previous study, in particular, highlighted a potential method for increasing the efficacy of gene therapy treatment to result in a clinically significant lowering of plasma cholesterol. We found that administration of pravastatin significantly increased luciferase expression from the LDLR promoter in vivo. This suggests that treatments designed to reduce cholesterol production in the liver could function as an effective pairing for traditional gene therapy in the context of FH. Statins work by inhibiting the conversion of HMG CoA to mevalonic acid catalysed by HMG CoA reductase (HMGCR), the rate-limiting step in the de novo synthesis of cholesterol pathway. In our previous study, we demonstrated that co-treatment with statins lead to a fivefold increase in transgene expression from the LDLR genomic promoter.
In this current study, we investigate whether the more specific approach of RNA interference-mediated knockdown of HMGCR protein might result in a greater reduction in hepatic cholesterol production and therefore, a more profound increase in transgene expression. Here we show that targeted knockdown of HMGCR leads to a robust increase in LDLR expression in vitro, which translates to a significant improvement in lowering of plasma LDL in vivo following gene-replacement gene therapy.
RESULTS AND DISCUSSION
Increased binding and internalisation of DiI-LDL in response to HMGCR siRNA transfection in human and mouse cell lines We first investigated whether transfection of small interfering RNA (siRNA) targeted against HMGCR in a human hepatocyte cell line would lead to a detectable lowering of HMGCR protein levels. Human Hep3b cells were transfected with siRNA oligonucleotides (between 20 and 150 nM) specific for human HMGCR or control siRNA (150 nM). Protein collected 24 h after transfection was resolved using SDS-PAGE, and the efficiency of HMGCR protein knockdown was determined by western blotting and quantification of chemiluminesence. Efficient HMGCR protein knockdown of up to 70% was observed in three independent experiments when siRNA concentrations over 100 nM were used (Figure 1a) . Hep3b cells were then transfected with 100 nM of siRNA and analysed for changes in specific binding and internalisation of LDL using fluorescently labelled LDL (DiI-LDL). Cells transfected with the HMGCR-targeted siRNA oligonucleotide show a profound increase in binding and internalisation of DiI-LDL (Figure 1b) . This indicated that reducing the level of HMGCR protein present inside the cell had a significant effect on cholesterol biosynthesis, leading to an increase in LDLR gene expression to compensate for the reduction in de novo synthesis.
We next assessed whether this effect could be observed in mouse cells. We initially performed a dose-response of siRNAs and found 100 nM to be the most effective dose in mouse Hepa 1-6 cells (data not shown). Hepa 1-6 cells were next transfected with 100 nM of siRNA Figure 1c ). This was confirmed in three independent experiments. In the Hepa 1-6 cells, knockdown was no longer detectable by 24 h post-transfection. This loss of knockdown was only observed in the Hepa 1-6 cells, most likely because of the much higher growth rate observed in Hepa1-6 cells compared with Hep3b cells resulted in an increased demand for sterols to facilitate membrane biosynthesis and cell division, which may have overcome the silencing effect of the siRNA oligonucleotides. We next examined specific binding and internalisation of LDL at 24 h post-transfection to confirm that Hmgcr knockdown in Hepa 1-6 cells resulted in a reduction of sterols in the cells and an upregulation of Ldlr expression. We show a robust increase in binding and internalisation of DiI-LDL confirming an upregulation of Ldlr gene expression (Figure 1d) .
Overall, siRNA-mediated knockdown of HMGCR or Hmgcr in human and mouse lines, respectively, elevated LDLR or Ldlr expression. These data suggested that siRNA-mediated knockdown of HMGCR or Hmgcr could increase LDLR transgene expression in a therapeutic setting.
Co-delivery of LDLR expression plasmids with siRNA in vivo
To test whether this result using siRNA would translate in vivo in a gene therapy protocol, we next investigated the effect that the siRNA oligonucleotides had on the expression from the LDLR promoter in vivo. To perform this we used pLDLR-Luc, 20 a plasmid containing the 10-kb LDLR promoter element driving a luciferase reporter gene (Figure 2a) , which has been previously used to investigate promoter expression dynamics in vivo using live animal imaging. 20 Female MF-1 mice were injected using hydrodynamic tail vein injection with either the pLDLR-Luc plasmid (n¼6) or a pCMV-Luc plasmid (n¼6), and three animals from each group were also injected with 40 mg kg À1 siRNA oligos. One week following injection, animals injected with the pLDLR-Luc plasmid and the siRNA targeted to Hmgcr had a 300-fold increase in luciferase expression levels compared with animals treated with the pLDLR-Luc plasmid alone (Figure 2b ). In contrast, the pCMV-Luc-injected animals showed no difference in luciferase expression levels in response to siRNA injection confirming that the Hmgcr siRNA-mediated induction of the LDLR promoter activity was specific to the LDLR promoter and not a general effect on vector transcription.
We next investigated the temporal dynamics of LDLR promoter induction following siRNA injection. MF-1 female mice were injected with pLDLR-Luc plasmid alone (n¼10) or pLDLR-Luc plasmid and either 40 mg kg À1 of scrambled control siRNA (n¼10) or Hmgcrspecific siRNA (n¼10). LDLR promoter induction was observed as early as 48 h after injection (Figure 2c) . By 1 week after injection, LDLR promoter induction reached a 20-fold increase as measured by luciferase expression compared with pLDLR-Luc only and scrambled siRNA-injected controls. Importantly, animals injected with scrambled control siRNA showed no increase in luciferase expression from the LDLR promoter, confirming nonspecific siRNA-mediated effects do not contribute to LDLR promoter induction.
Co-expression of LDLR expression plasmids with microRNA to Hmgcr in vivo We wanted to further investigate the use of Hmgcr knockdown in the context of gene therapy. Recent work has identified microRNA (miRNA) expression cassettes as a safer option for expression of RNA interference oligonucleotides in vivo compared with siRNA oligomers or traditional short hairpin RNA cassettes. 21 Overexpression from short hairpin RNA expression cassettes has been shown to lead to disruptions in the miRNA biogenesis pathways. In contrast, miRNAs are expressed as primary miRNA transcripts, which enter the endogenous processing pathway, which involves processing into pre-miRNAs by Drosha-DGCR8 complex and export into the cytoplasm for processing into functional siRNAs. However, short hairpin RNAi-mediated knockdown of HMG CoA reductase in vivo O Hibbitt et al RNA transcripts do not enter the endogenous pathway, instead they are exported straight from the nucleus and processed by Dicer. Using the BlockIT polII miRNA expression system (Invitrogen Ltd, Paisley, UK), we generated a series of four plasmids containing four different pre-designed oligonucleotides specific for mouse Hmgcr.
To investigate whether the miRNA expression vectors would result in an upregulation of luciferase expression from the LDLR promoter in vivo comparable to the siRNA oligos, we co-injected the four plasmids together with the pLDLR-Luc plasmid into MF-1 females. Ten MF-1 female mice were hydrodynamically injected with pLDLRLuc (50 mg). Five animals were also injected with all four miRNA plasmids (5 mg per plasmid) to ensure maximal knockdown. The mice were assessed for luciferase expression at 24 h and 10 days following injection using an IVIS live luciferase imaging camera (Caliper Life Sciences, Hopkinton, MA, USA). In both groups, luciferase expression levels showed the typical acute reduction in luciferase expression. Data were normalised to the 24-h luciferase levels as described previously. 20 Animals injected with the miRNA expression plasmids showed a 12-fold increase in luciferase expression levels at the 10 day timepoint when compared with animals injected with the pLDLR-Luc plasmid only (Figure 3a) . These data suggest that expression of the miRNAs resulted in the knockdown of Hmgcr, leading to an inhibition of de novo synthesis of cholesterol in vivo, leading to a profound increase in activity of the LDLR promoter.
Co-expression of miRNA against Hmgcr and the pLDLR-LDLR transgene in Ldlr À/À mice We next investigated whether injection of miRNA expression vectors together with the pLDLR-LDLR plasmid would lead to enhanced cholesterol lowering in Ldlr À/À mice. The pLDLR-LDLR plasmid contains the 10-kb LDLR promoter driving the human LDLR cDNA. 20 We injected 10-week-old female Ldlr À/À mice using hydrodynamic tail vein injection with either pLDLR-LDLR alone (50 mg) or pLDLR-LDLR (50 mg) plus all four miRNA plasmids (5 mg per plasmid). Mice were killed 2 weeks following injection and blood was collected for analysis of plasma LDL concentrations. Four untreated Ldlr À/À animals were killed as untreated controls. Animals injected with pLDLR-LDLR plasmids show a significant reduction in plasma cholesterol compared with untreated Ldlr À/À controls (Figure 3b ; P¼0.00035 by Student's t-test). Animals, which were injected with the miRNA plasmids showed a significant difference in plasma LDL concentrations compared with animals injected with the pLDLR-LDLR plasmid alone (Figure 3b ; P¼0.0036 by Student's t-test).
Our work has demonstrated for the first time that targeted knockdown of Hmgcr enhances the therapeutic efficacy of LDLR gene therapy for FH in an animal model of the condition. Targeted knockdown of Hmgcr led to increased binding and internalisation of DiI-LDL in vitro, and an enhancement of gene expression and therapeutic effect in vivo. These data are encouraging and support the idea that therapeutic outcome can be improved in gene therapy protocols by using combinatorial therapy. Our previous work showed that co-treatment with statins led to an increase in gene expression from the LDLR promoter in vivo. This current study goes further and shows that targeted knockdown of Hmgcr/HMGCR leads to an enhanced lowering of plasma LDL cholesterol when combined with LDLR gene-replacement therapy. Although generally well-tolerated statins can exhibit side effects, such as muscle pain, rhabdomyolysis and kidney failure, muscle weakness and peripheral neuropathy, which although rare, can be serious. A more specific gene targeting approach may avoid this. Both approaches offer the opportunity to increase the power of gene transfer by manipulating gene expression using cellular physiological pathways following delivery. A comparison between the potential benefits of co-treatment with either statins or siRNA on therapeutic effect, safety and long-term efficacy would be interesting.
The treatment of FH with gene therapy has been the focus of many research papers. However, translation of animal studies into the clinic has not been entirely successful, possibly because of the confounding issue of de novo cholesterol synthesis. There has previously been some evidence to suggest that transduced cells are lost through cytotoxic cholesterol accumulations. 15, 16 This is the first study to successfully demonstrate the efficacy of the combination of gene knockdown and gene replacement for FH, and further efforts are currently underway to assess combination gene therapy in the long term. 
MATERIALS AND METHODS Plasmids
The pLDLR-Luc and pLDLR-LDLR plasmids were generated as described. 20 Predesigned and validated siRNA oligonucleotides specific for human HMGCR (siRNA identification s141) and mouse Hmgcr (siRNA identification s67591), as well as scrambled control oligonucleotides were obtained from Ambion (Applied Biosystems, Warrington, UK). The miRNA expression plasmids were generated according to the manufacturer's instructions (Invitrogen). Briefly, four commercially avaliable BLOCKit miRNA oligos were selected that targeted the mouse Hmgcr gene (Hmgcr BLOCK-IT miR RNA interference select mmi511180, mmi511181, mmi511182, mmi511183). Oligonucleotide sense and antisense strands were annealed and then cloned into the BLOCKit miRNA vector using TOPO cloning. Vectors were then transformed into TOP10 chemically competent cells and plated onto LB agar containing 50 mg ml À1 spectinomycin.
Cell culture
Human Hep3b cells were a kind gift from Dr Zoe Holloway. Mouse Hepa 1-6 cells were a kind gift from Dr Natalia Sacilotto. Both cell lines were grown in Dulbecco's modified Eagle's medium (10% fetal bovine serum, 1% penicillin/ streptomycin, 1% L-glutamine). Cells were transfected with siRNA oligonucleotides as previously described. 22, 23 Cells were collected at the specified time points, and protein extracted for SDS-PAGE. Relative protein levels were assessed using a chemiluminescent imager (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) and Quantity one software after immunoblotting with HMGCR polyclonal antibody (C-18, Santa Cruz Biotechnology, Inc., Heidelberg, Germany). Loading levels were controlled using a mouse monoclonal b-actin antibody (AC-15, Abcam, Cambridge, UK). Specific binding and internalisation of LDL was assessed using DiI-LDL assay as previously described. 20, 24 Experiments were performed in quadruplicate.
Animals
Female MF-1 mice, an outbred strain used previously, 20, 25 were obtained from Harlan (Blackthorn, UK). Ldlr À/À mice on a C57B/6.Sv9 hybrid background were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and maintained as a homozygous knockout colony at the University of Oxford Animal Facilities. All animals were housed on a 12:12 light cycle, and fed ad libitum. All animal procedures were conducted in accordance with the Animals (Scientific Procedures) Act 1986, and after appropriate ethical review.
Hydrodynamic delivery, imaging and plasma analysis
Animals weighing 25-30 g received hydrodynamic tail vein injections of plasmid DNA as described. 20, 25 Animals were imaged using an IVIS Lumina luciferase imaging camera (Caliper Life Sciences). Before imaging, animals were anaethetised with isofluorane and given a 100-ml intraperitoneal injection of a 15 mg ml À1 luciferin solution (in phosphate-buffered saline, Caliper Life Sciences). Animals were placed inside the chamber and were maintained under anaesthesia for the duration of the imaging. Following a 4-min incubation period, images were taken, and luciferase expression was quantified using LivingImage software (Caliper Life Sciences). Animals were allowed to recover and left for an appropriate amount of time before killing. Blood was collected following killing and centrifuged at 5000 r.p.m. for 10 min to separate plasma. Plasma LDL content was analysed using a COBAS (Roche, Burgess Hill, UK) clinical chemistry analyser.
